Cancer experts ID biomarker for early-stage lung cancer

Lung cancer has always been tough to detect at an early stage, proving an elusive foe for a number of proposed screening tests. But a group of cancer experts at the M.D. Anderson Cancer Center say that a protein that binds to DNA could prove to be the biomarker needed to make early detection--and swift treatment--into a reality.

The protein is dubbed TCF21, a transcription factor that goes awry through hypermethelation, spurring the cancer. "We were very excited to find evidence of TCF21 hypermethylation in 105 non-small-cell lung cancers of different stages and types, which we then validated by looking at another 300 cases using a tissue microarray," said Kristy Richards, who led the research.

"More than 80 percent of these cancers show some abnormal expression of this biomarker, meaning that it is a promising target for developing a screening tool. This is important to physicians and patients because surgery and other treatments can be much more effective before the cancer has the opportunity to spread."

- here's the story from Medical News Today

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.